生物技术巨头Moderna, Inc.近日披露,其研发的mRNA-1010疫苗有望在2026年获得首批潜在上市批准。不过该时间节点的实现,仍需以当前多项正在推进的监管审查流程的最终结果为准。公司强调,审批进程将受到全球各监管机构对疫苗安全性、有效性数据的持续评估影响。
生物技术巨头Moderna, Inc.近日披露,其研发的mRNA-1010疫苗有望在2026年获得首批潜在上市批准。不过该时间节点的实现,仍需以当前多项正在推进的监管审查流程的最终结果为准。公司强调,审批进程将受到全球各监管机构对疫苗安全性、有效性数据的持续评估影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.